A recent meta-analysis found that CRP can be used as a possible prognostic indicator for a variety of gynecologic malignancies, such as cervical cancer, ovarian cancer, endometrial cancer, and vulvar cancer [839]. This evidence concerns the gene CRP and ovarian carcinoma.